Conditions favor biotech outperformance of broader markets for at least a few more quarters. Outsourcing offers biotech firms varied advantages, from cost reduction to enhancing credibility. The sector’s success and the outsourcing trend is fueling ancillary businesses, notably specialty REITs, CROs and research tools companies. As biotech indices continue to surpass all-time highs, one must
Aaron Reames, Senior Equity Analyst
Aaron Reames is a senior analyst for Columbia Management Investment Advisers, LLC. Mr. Reames is responsible for equity research covering the biotechnology and emerging specialty pharmaceutical sectors. He joined the firm in 2010 and has been a member of the investment community since 1998.
Prior to joining the firm, Mr. Reames worked as a senior analyst at Wells Fargo Securities (formerly Wachovia), where he was a director, equity researcher and senior analyst covering the biotechnology sector. Prior to that, Mr. Reames worked for A G Edwards, where he was a vice president covering the same area.
Before beginning his career as a sell-side analyst, Mr. Reames was director of the Biotechnology Group at JPS Capital and a performance measurement and investment analyst at Banc One Investment Advisors, the investment arm for Bank One Corporation (now JPMorgan Chase & Co.)
Mr. Reames earned his B.S. in biology from Ohio State University and his M.B.A. from Franklin University in Columbus, Ohio.